The DEA Banned Ibogaine in 1970. This Week, Three Federal Agencies Bet on It Anyway.

Sam Juan spent years running direct-action missions as a Cultural Support Team leader attached to Navy SEAL teams — one of the only women in the room, doing work she still won’t fully describe. When she came home, she did what a lot of veterans in her position do with what they’re carrying. “For a long time, I self-medicated,” she told DAV last year. “It was either a ton of work, or all the substances. Alcohol, drugs, you name it, right?” Eventually that included opioids. Eventually she flew to Mexico, because the treatment that actually worked for her isn’t legal to give her here.

The federal government spent 56 years treating that plant as a threat to be scheduled away. This week, it started treating it as a research priority to be funded instead — and the distance between those two things is exactly where thousands of veterans like Sam Juan have been living.

On July 13, HHS and the Department of Veterans Affairs signed a five-year, renewable memorandum of understanding — an MOU, the formal paperwork two federal agencies sign to commit to working together on something specific — to coordinate psychedelic drug research, share clinical protocols, and build a training pipeline for the workforce that will eventually deliver this care. The VA’s own announcement put the number of active VA psychedelic trials already underway at more than 20. The same week, the FDA finalized its first clinical-trial guidance for psychedelic drug developers and scheduled a public hearing, and ARPA-H — the government’s newer, DARPA-styled health research agency — opened a funding call written specifically around one compound and one diagnosis: ibogaine for opioid use disorder.

If you are the person self-medicating right now — the drink, the pills, the anything that quiets the noise down enough to function — none of this changes what you can walk into a clinic and legally receive in the United States today. That’s the honest, unglamorous first fact of this story, and it’s the one most of this week’s coverage buried under the press-release optimism. But it does change, in a durable and measurable way, where three federal agencies are pointing money, staff time, and regulatory attention for the first time in the fifty-six years since ibogaine was placed in the same legal category as heroin. We covered the FDA’s trial-design guidance and its veteran-safety provisions in detail earlier this week; this piece is about the specific bet ARPA-H and NIDA are now placing on ibogaine for opioid use disorder — and the veteran who already made that bet on herself, years before Washington was willing to fund the science.

Three agencies moved in the same direction on purpose, and that almost never happens

Federal health policy rarely moves as a coordinated front. What happened on July 13 and the days around it was unusually synchronized. HHS Secretary Robert F. Kennedy Jr. framed it as a debt: “America owes every veteran the best care our nation can provide. We’re not going to wait while promising treatments sit on the sidelines.” VA Secretary Doug Collins tied it directly to the April 2026 executive order that set this whole sequence in motion: “President Trump opened up a world of possibility for treating veterans and others with mental health conditions, and VA is proud to be part of this important work.” FDA Acting Commissioner Kyle Diamantas connected it specifically to addiction: “Too many Americans and their families continue to be affected by substance use disorder and serious mental illness, and we have a responsibility to pursue every appropriate opportunity to advance new treatment options.”

The mechanics behind the statements are where this gets concrete. The FDA’s new guidance solves a problem that helped sink the last major psychedelic drug application: when Lykos Therapeutics submitted MDMA for PTSD to the FDA in 2024, regulators rejected it largely over “functional unblinding” — the simple, stubborn fact that if you’re handed a psychedelic in a clinical trial, you usually know within the hour that you didn’t get the sugar pill, which undermines the placebo-controlled design the FDA normally requires to prove a drug, not a expectation, caused the improvement. The new guidance lets sponsors use active comparators or low sub-perceptual doses instead of an inert placebo, requires two trained clinical observers per dosing session, and sets a public hearing for September 14 at FDA’s White Oak campus to work through the harder policy questions. In parallel, ARPA-H Director Alicia Jackson put a number on the problem her agency’s ibogaine call is meant to address: “Treatment for opioid use disorder has been stuck in an innovation rut for decades, and Americans are paying a heartbreaking price.” NIDA has already put money behind that framing, awarding $2.3 million toward an Investigational New Drug application — the formal FDA filing required before any unapproved drug can legally be tested on people — specifically for ibogaine.

None of these four agencies needed to move together. They chose to, in the same two-week window, which is the part of this story that separates it from the usual single-press-release policy and funding news cycle providers scroll past.

Washington has done this before — banned first, studied decades later, and counted the cost of the gap out loud

This is not the first time a federal agency has decided, years after the fact, that something it outlawed might have been worth keeping. In 1962, a 19-year-old heroin user named Howard Lotsof took ibogaine recreationally with five friends who were also using heroin, and all six noticed something nobody expected: their withdrawal symptoms and cravings had simply stopped. Lotsof spent the next several decades trying to get anyone in American medicine to take that seriously, eventually patenting ibogaine’s anti-addictive applications in 1985. It didn’t matter. In 1970, ibogaine had been swept into Schedule I along with the rest of the era’s psychedelics — the category reserved for drugs the DEA says have no accepted medical use and a high potential for abuse, the same shelf heroin sits on. A naturally occurring plant compound is hard to patent and impossible for a pharmaceutical company to build a profitable moat around, and addiction medicine has never been where the industry’s money wanted to go anyway. So ibogaine spent the next five decades doing its work almost entirely offshore — in clinics in Mexico, Costa Rica, and elsewhere — reachable only by people with the money and the desperation to fly there, while it stayed illegal to prescribe in the one country running the world’s deadliest overdose crisis. We have watched this exact shape before, with methadone clinics that communities fought for decades to keep out of their neighborhoods, and with syringe exchanges that Congress banned from receiving federal funds for 21 years while HIV spread among people who inject drugs. The pattern is not that America refuses to eventually study what works. It’s that “eventually” tends to run for decades, on a clock set by stigma rather than evidence, while the people who needed the treatment sooner did what Sam Juan did: left.

Lotsof spent the next several decades trying to get anyone in American medicine to take that seriously, eventually patenting ibogaine’s anti-addictive applications in 1985.

The part the press release leaves out: a funding call is not a treatment you can get

Here is the caveat a clinician reading this coverage will already be forming, and it deserves to be said as plainly as the good news above it: ibogaine remains fully Schedule I under federal law. Nothing signed on July 13 makes it legal for a single provider in the United States to prescribe it to a single patient tomorrow. What changed is upstream of that — research infrastructure, funding priority, and regulatory clarity for the trials that would eventually have to happen before any rescheduling or approval could follow. That gap between “the government is now funding the science” and “you can get this at a VA clinic next year” is measured in years, not months, and reporting that framed this week’s news as veterans-can-now-access-ibogaine would have been simply wrong.

There’s a second layer under that, and it’s psychological as much as regulatory. RAND’s Center for Well-Being tracked something worth sitting with: nearly 4.8 million U.S. veterans have already used psilocybin, LSD, or MDMA in their lifetime — 19.6% report LSD, 18.6% psilocybin — and close to half of them, 48%, said they weren’t sure whether telling a VA provider about that history would put their benefits at risk. That’s not a footnote. It’s the mechanism by which a policy shift at the federal level takes years to reach an actual exam room: a veteran has to trust that disclosing what already helped them won’t be held against them, before any newly funded research pipeline can even enroll them as a participant. Ron Adkins, an Army Reserve veteran who has become an advocate on this issue, put the clinical humility part of it well to Military Times: “The cognitive space is a very complex environment… the treatments that might work very well for one person could be wholly ineffective for another.” That’s not a hedge to bury a claim — it’s the specific, named uncertainty a good clinician wants named out loud before anyone oversells a plant alkaloid as a cure. Coverage the same week from Marijuana Moment noted the same officials pointing to the FDA’s 2024 rejection of Lykos Therapeutics’ MDMA application for PTSD as the cautionary tale this new trial-design guidance is explicitly meant to avoid repeating.

What this actually means for opioid use disorder, specifically

Ibogaine’s current federal moment is arriving through the psychedelics-and-veterans door, but ARPA-H’s funding call is explicit about targeting opioid use disorder directly — an estimated 5.7 million Americans, per the agency’s own framing of the problem it’s funding against. That distinction matters for a reason that has nothing to do with psychedelics and everything to do with what already works: buprenorphine, methadone, and naloxone are legal, available, and effective right now, today, for opioid use disorder, in a way ibogaine is not and won’t be for years. Nothing in this week’s news changes that. If you or someone you’re caring for is dealing with opioid use disorder tonight, the treatments that exist right now are not a placeholder while the country waits for ibogaine — they are the thing that is actually proven to keep people alive in 2026, and this policy shift doesn’t replace them; at best, years from now, it adds to them.

What this week’s coordinated push does mean is that the federal government has, for the first time, put a name and a dollar figure on taking seriously what people like Sam Juan have been saying for years without a research infrastructure behind them. She described her own ibogaine experience without softening it: “It was very dark for me… I kept feeling like I saw spirits, dark shadows.” She also described what came out the other side of it, about the opioid use she’d been managing on her own: “I have not even thought about doing an opiate since then. I couldn’t care less about it.” Whatever a Phase 2 trial eventually finds about mechanism, dose, and who it helps and who it doesn’t, that’s the sentence three federal agencies just decided was worth the money to go find the science under, instead of leaving people to find it in a clinic in another country because their own government had already decided the question in 1970 and never bothered to look again. Juan’s verdict on the whole thing, unresearched and unregulated as it was when she went: “I would do this 100 times over.” The honest measure of this week’s news isn’t whether it proves her right. It’s whether it’s the first step toward making sure the next veteran who needs an answer doesn’t have to leave the country to get one.

It’s whether it’s the first step toward making sure the next veteran who needs an answer doesn’t have to leave the country to get one.